P

Inventor

MORTENSEN DEBORAH

US16 patents
⚠️ This page may combine multiple inventors who share the name “MORTENSEN DEBORAH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SIGNAL PHARM LLC

12 patents
US9771371B2Sep 26, 2017

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

SIGNAL PHARM LLC4 citations83
US8907087B2Dec 9, 2014

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

SIGNAL PHARM LLC4 citations83
US9556126B2Jan 31, 2017

Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith

SIGNAL PHARM LLC10 citations82
US9156798B2Oct 13, 2015

Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith

SIGNAL PHARM LLC5 citations82
US9155736B2Oct 13, 2015

Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity

SIGNAL PHARM LLC16 citations82
US9079900B2Jul 14, 2015

Methods of synthesis and purification of heteroaryl compounds

SIGNAL PHARM LLC5 citations82
US10167290B2Jan 1, 2019

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

SIGNAL PHARM LLC1 citations72
US9783505B2Oct 10, 2017

Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith

SIGNAL PHARM LLC2 citations71
US11292796B2Apr 5, 2022

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

SIGNAL PHARM LLC0 citations62
US10683298B2Jun 16, 2020

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

SIGNAL PHARM LLC0 citations51
US9193692B2Nov 24, 2015

Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors

SIGNAL PHARM LLC0 citations51
US9557338B2Jan 31, 2017

Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity

SIGNAL PHARM LLC1 citations50

PERRIN-NINKOVIC SOPHIE

3 patents

HARRIS ROY L

1 patent